Testing Stapokibart for moderate to severe bullous pemphigoid
Treatments studied
Part of Immune system & allergy, Skin clinical trials.
This trial tests a new injectable drug, Stapokibart, for people with moderate to severe bullous pemphigoid, a blistering skin condition. The goal is to see if the drug can help reduce blistering and itching.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 90 years old.
- You have been diagnosed with bullous pemphigoid (a blistering skin disease).
- Your bullous pemphigoid is moderate to severe, with significant skin blistering and daily itching.
- You are generally able to care for yourself (Karnofsky score of 50% or higher).
- You do not have other blistering skin diseases or skin conditions that would interfere with the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental medication (Stapokibart) for children ages 2 to 11 with moderate-to-severe eczema that hasn't improved with topical creams. The goal is to see if the new treatment can help control their symptoms.
This study tests a new injection medicine called Stapokibart for treating atopic dermatitis (a chronic skin condition causing itching and inflammation). Your doctor has already decided this medicine might help you before you joined the study.
This trial tests a medicine called Stapokibatrt in children with atopic dermatitis (eczema). It is for kids who already completed the main study and may help manage their skin condition.
Stapokibart is a new injection that works on a key pathway involved in allergy symptoms. This study will test if this once-every-two-week shot can help reduce runny nose, sneezing, and itchy eyes in people with allergic rhinitis (hay fever).
This study tests a new injection called Stapokibart for people with seasonal allergic rhinitis (hay fever triggered by pollen or mold). The goal is to see if it helps control symptoms like sneezing, runny nose, and itchy eyes.
This trial tests a new biologic medicine (injection) to see if it can better control seasonal allergy symptoms in teens who haven't had good relief from standard treatments like nasal sprays.
Hear when a new Bullous Pemphigoid (BP) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.